PMID- 36672336
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230123
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 2
DP  - 2023 Jan 6
TI  - Multiomics Analysis Reveals Cuproptosis-Related Signature for Evaluating 
      Prognosis and Immunotherapy Efficacy in Colorectal Cancer.
LID - 10.3390/cancers15020387 [doi]
LID - 387
AB  - Cuproptosis is a copper-induced form of mitochondrial cell death which is engaged 
      in the proliferation and migration of a variety of tumors. Nevertheless, the role 
      of cuproptosis in tumor microenvironment (TME) remodeling and antitumor therapy 
      is still poorly understood. We characterized two diverse cuproptosis-associated 
      molecular isoforms in CRC which exhibit distinct prognostic and TME 
      characteristics. Subsequently, we constructed a cuproptosis-associated prognostic 
      model containing five genes and divided the patients into a high CPS-score group 
      and a low CPS-score group. Univariate and multivariate Cox analyses showed that 
      the CPS score could be used as an independent prognostic factor. The nomogram, 
      and its consequent calibration curves, indicated that this prognostic signature 
      had good predictive power for CRC. The analysis of single-cell sequencing data 
      showed the significant expression of HES4 and SPHK1 in various immune and stromal 
      (including fibroblasts) cells. Further studies showed that tumor mutational 
      burden (TMB), high microsatellite instability (MSI-H) ratio, immune checkpoint 
      blockade (ICB), and human leukocyte antigen (HLA) gene expression all positively 
      correlated with the CPS score, predicting a better reaction to immunotherapy in 
      high CPS-core patients. The CPS score constructed from cuproptosis subtypes can 
      be used as a predictive tool to evaluate the prognosis of CRC patients and their 
      response to immunotherapy.
FAU - He, Rong
AU  - He R
AUID- ORCID: 0000-0002-3856-8860
AD  - Department of Oncology, Shanghai Tenth People's Hospital, School of Medicine, 
      Tongji University, Shanghai 200072, China.
FAU - Zhang, Heping
AU  - Zhang H
AD  - Department of Oncology, Shanghai Tenth People's Hospital, School of Medicine, 
      Tongji University, Shanghai 200072, China.
FAU - Zhao, Huaxin
AU  - Zhao H
AUID- ORCID: 0000-0003-0545-8320
AD  - Department of Oncology, Shanghai Tenth People's Hospital, School of Medicine, 
      Tongji University, Shanghai 200072, China.
FAU - Yin, Xiaolan
AU  - Yin X
AD  - Department of Oncology, Shanghai Tenth People's Hospital, School of Medicine, 
      Tongji University, Shanghai 200072, China.
FAU - Lu, Jingyi
AU  - Lu J
AD  - Department of Oncology, Shanghai Tenth People's Hospital, School of Medicine, 
      Tongji University, Shanghai 200072, China.
FAU - Gu, Cheng
AU  - Gu C
AD  - Department of Oncology, Shanghai Tenth People's Hospital, School of Medicine, 
      Tongji University, Shanghai 200072, China.
FAU - Gao, Jie
AU  - Gao J
AD  - Department of Oncology, Shanghai Tenth People's Hospital, School of Medicine, 
      Tongji University, Shanghai 200072, China.
FAU - Xu, Qing
AU  - Xu Q
AD  - Department of Oncology, Shanghai Tenth People's Hospital, School of Medicine, 
      Tongji University, Shanghai 200072, China.
LA  - eng
GR  - SHDC2022CRTO09/Collaborative Special Project on Medical-Enterprise Integration 
      and Innovation/
GR  - 21S21901500/Shanghai Municipal Science Commission Innovation and Inheritance of 
      Traditional Chinese Medicine/
GR  - 18DZ1910102/Shanghai Science and Technology Commission 
      Industry-University-Research-Medical Project/
PT  - Journal Article
DEP - 20230106
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9856392
OTO - NOTNLM
OT  - colorectal cancer
OT  - cuproptosis
OT  - immunotherapy
OT  - prognostic signature
OT  - single-cell analysis
COIS- The authors declare that the study was carried out without any commercial or 
      financial relationships which could be considered a potential conflict of 
      interest.
EDAT- 2023/01/22 06:00
MHDA- 2023/01/22 06:01
PMCR- 2023/01/06
CRDT- 2023/01/21 01:12
PHST- 2022/12/07 00:00 [received]
PHST- 2022/12/30 00:00 [revised]
PHST- 2023/01/04 00:00 [accepted]
PHST- 2023/01/21 01:12 [entrez]
PHST- 2023/01/22 06:00 [pubmed]
PHST- 2023/01/22 06:01 [medline]
PHST- 2023/01/06 00:00 [pmc-release]
AID - cancers15020387 [pii]
AID - cancers-15-00387 [pii]
AID - 10.3390/cancers15020387 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Jan 6;15(2):387. doi: 10.3390/cancers15020387.